Progenics Pharmaceuticals, Inc. (PGNX) Stock Trading Halted Today; FDA Advisory Committee To Consider And Provide Recommendations Regarding Peripherally-Acting Opioid Receptor Antagonists
6/11/2014 7:12:29 AM
TARRYTOWN, N.Y., June 11, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that NASDAQ has halted trading of the company's common stock.
The U.S. Food and Drug Administration's Anesthetic and Analgesic Drug Products Advisory Committee is meeting today and tomorrow, June 11 and 12, to discuss the potential cardiovascular risk associated with products in the class of peripherally-acting opioid receptor antagonists and the necessity, timing, design and size of cardiovascular outcomes trials to support approval of products in the class for the proposed indication of opioid-induced constipation in patients taking opioids for chronic pain.
Help employers find you! Check out all the jobs and post your resume.
comments powered by